BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Remedent, Inc. (REMI.OB) Release: Glamsmile Opens Shanghai Studio on February 21, 2011


2/24/2011 8:35:05 AM

DEURLE, BELGIUM--(Marketwire - February 23, 2011) - Remedent, Inc. (OTCBB: REMI), an international company specializing in research, development, and the manufacturing of oral and cosmetic dentistry products, opened its largest four chair facility in Shanghai yesterday.

"We are all excited about our biggest Studio opening in potentially the best city in the world for veneers , Shanghai, on Monday. Shanghai is one of the most galvanic cities in the world today. Its cosmopolitan character, sophisticated and affluent consumers and highly educated labor force, make it one of the most exciting locations we have. With a population of approximately 19 million people plus the fact that many of the residents suffer with tetracycline stains, makes Glamsmile the only operation of its kind, a terrific fit for Shanghai," said Guy De Vreese, CEO of Remedent.

"On opening day we seated two cases and we believe that there is potential for our Shanghai Studio to follow or most likely exceed the projected monthly cases of our other successful Studios in both Hong Kong and Beijing in the near future, especially considering that we anticipate our revenues in Beijing will increase by approximately by 50% from the prior fiscal year," said Guy De Vreese.

About Remedent

Remedent, Inc. specializes in the research, development, manufacturing and the marketing of oral care and cosmetic dental products. The company serves the professional dental industry with breakthrough technology for dental veneers. These products are supported by a line of professional veneer whitening and tooth sensitivity solutions. Headquartered in Belgium, Remedent distributes its products to more than 55 countries worldwide. For more information, go to www.remedent.be, glamsmile.com and glamsmile.cn.

Forward-Looking Statements

Statements in this press release that are "forward-looking statements" are based on current expectations and assumptions that are subject to risks and uncertainties. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Remedent's actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as "believes," "belief," "expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," "projects," "project," to be uncertain and forward-looking. Actual results could differ materially because of factors such as Remedent's ability to achieve the value creation and results of operations as contemplated by its business plans and objectives, and the risks related to expansion and growth. For further information regarding risks and uncertainties associated with Remedent's business, please refer to the risk factors described in Remedent's filings with the Securities and Exchange Commission, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. We undertake no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.


CONTACT:
Stephen Ross
310 922 5685
docktor99@aol.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES